Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
NCT02297958 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28
Last updated 2020-08-31
Summary
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Conditions
- Ovarian Carcinoma
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Principal Investigators
-
Vincent Lavoue, PH · Rennes University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-15
- Primary Completion
- 2019-07-27
- Completion
- 2019-07-27
Countries
- France
Study Locations
More Related Trials
-
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
NCT03491033 ·Status: COMPLETED
-
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351 ·Status: COMPLETED ·Phase: NA
-
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771 ·Status: RECRUITING
-
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
NCT06304922 ·Status: NOT_YET_RECRUITING
-
The Effect of TRA-8 on Ovarian Cancer Tissue
NCT00711932 ·Status: COMPLETED
-
Improving Quality of Care for Patients With Recurrent Ovarian Cancer
NCT02809339 ·Status: UNKNOWN
-
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195 ·Status: RECRUITING ·Phase: NA
-
Tumor Gene Expression in Women With Ovarian Cancer
NCT00817479 ·Status: COMPLETED ·Phase: PHASE4
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
NCT02323568 ·Status: COMPLETED ·Phase: NA
-
Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia
NCT04001023 ·Status: RECRUITING ·Phase: NA
-
Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
NCT00452985 ·Status: COMPLETED
-
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00288275 ·Status: TERMINATED
-
Spectroscopy in Ovarian Cancer
NCT04817449 ·Status: COMPLETED
-
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
NCT06775470 ·Status: RECRUITING
-
Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve
NCT00712452 ·Status: TERMINATED ·Phase: NA
-
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
NCT02973750 ·Status: COMPLETED
-
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT01313078 ·Status: COMPLETED ·Phase: PHASE2
-
The Treatment Preferences of Women Diagnosed With Ovarian Cancer
NCT03367260 ·Status: COMPLETED
-
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
NCT00002913 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin
NCT02667925 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Long-Term Responders on Olaparib
NCT02489058 ·Status: COMPLETED
-
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
NCT01048814 ·Status: COMPLETED
-
Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine
NCT02774395 ·Status: COMPLETED
-
Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria
NCT06253559 ·Status: COMPLETED